Loss-of-function ferroportin disease: novel mechanistic insights and unanswered questions by Vlasveld, L.T. & Swinkels, D.W.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/200237
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
haematologica | 2018; 103(11)
EDITORIALS
1753
Loss-of-function ferroportin disease: novel mechanistic insights and unanswered questions
L. Tom Vlasveld1 and Dorine W. Swinkels2
1Department of Internal Medicine, Haaglanden Medical Center, Location Bronovo, The Hague and 2Translational Metabolic Laboratory,
Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
E-mail: dorine.swinkels@radboudumc.nl
doi:10.3324/haematol.2018.203315
Ferroportin, a 571 amino acid cation transporter encodedby the SLC40A1 gene, is the only known human cellulariron exporter and primarily expressed in the basolateral
membrane of duodenal enterocytes, macrophages, and hepa-
tocytes.1,2 By regulating ferroportin-mediated iron export in
these cells, the hepatocyte-derived peptide hormone hepcidin
plays a central role in intestinal iron resorption, macrophage
iron recycling and hepatic iron storage (Figure 1A).3 Functional
studies reveal the internalization of ferroportin upon hepcidin
binding with subsequent ubiquitination of the protein result-
ing in the diminution of cellular iron export. The mechanism
of the inhibition of cellular iron efflux is not fully elucidated.4
Genetic ferroportin variants result in autosomal dominantly
inherited hereditary hemochromatosis (HH) type 4 or ferro-
portin disease which is traditionally divided into two entities
primarily based on the pattern of cellular iron distribution.
Classical ferroportin disease (type 4A) is characterized by
macrophage iron retention and decreased circulating iron avail-
ability for erythropoiesis, and is clinically recognized by the
presence of elevated serum ferritin concentrations with low to
normal transferrin saturation (TSAT) and poor tolerance to
phlebotomy. Non-classical (atypical, type 4B or ferroportin-
associated HH) ferroportin disease is characterized by
parenchymal (hepatocellular) iron overload with both elevated
serum ferritin and TSAT and is indistinguishable from other
forms of HH.5
To assess the pathogenicity of a ferroportin variant function-
al studies on iron export and/or ferroportin expression are per-
formed in cell-lines (mostly HEK293T, a human embryonic
kidney cell line) transfected with the variant. However, inter-
pretation of results may be hampered by these studies being
done in non-enterocyte and non-macrophage cell lines.
Moreover, comparability between reports may have short-
comings, since iron loading and hepcidin exposure protocols,
the mode of iron export measurements and the determination
of ferroportin expression differ largely between studies.
Nevertheless, the results obtained are quite consistent, in that
patients with the type 4A phenotype are mostly associated
with loss-of-function ferroportin variants which display
decreased membrane expression and/or iron transport in func-
tional assays, while patients with the type 4B phenotype have
gain-of-function variants with preserved membrane expres-
sion and iron export capacity even after hepcidin exposure.
Notwithstanding a different pattern of cellular iron distribu-
tion, a review of numerous case series of ferroportin disease
reveals that in those patients who underwent magnetic reso-
nance imaging (MRI) or liver biopsy,  hepatic iron content is
increased for both types of ferroportin disease. These observa-
tions indicate that loss-of-function variants also result in body
iron overload. 
Variety in iron parameters reported for patients with ferro-
portin variants is large and the correlation between iron export
capacity in functional studies and clinical phenotype is poor,
especially on an individual level. The establishment of the
pathogenicity of ferroportin variants may not only be impeded
by the presence of iron homeostasis modulating co-morbidi-
ties such as alcohol consumption and liver steatosis, but also
by the limited applicability of in silico prediction models in the
absence of a fully elucidated three-dimensional (3D) structure
of ferroportin. In the most widely accepted secondary struc-
ture, ferroportin comprises 12 helices located in 12 transmem-
brane (TM) domains bound via six extracellular (ES) and five
intracellular (IS) segments with a large intracellular loop
between the 6th and 7th transmembrane helix and an intracellu-
larly located N- and C-terminus. The available 3D models are
based on a comparison with membrane transport proteins
from a wide range of other species with only a 10 - 24%
sequence homology and a maximal 40% similarity. Two stud-
ies, using E. coli glycerol-3-phosphate transporter GlpT and lac-
tose permease LacY or the Bdellovibrio bacteriovorus Bd2019 iron
transporter as template, respectively, reveal an open inward
and an open outward structure with an intra- and extracellular
gate between the 6th and 7th transmembrane domain.6,7 Site
mutagenetic and conformational studies revealed the residues,
located at IS1, IS2 and IS5, that are important in intracellular
gate interaction and the residues, located at TM1, TM12 and
ES1 and ES4, that are involved in extracellular gate interaction.
These studies also identified ferroportin residues that are
essential for binding and ubiquitination of hepcidin and may
be involved in iron binding and egress. The unequivocally hep-
cidin-resistant gain-of-function ferroportin variants Cys326Ser,
Tyr501Cys, Asp504Asn and Tyr64Asn and His507Arg are
reported to have impaired hepcidin binding and hepcidin-
dependent ubiquitination, respectively. In the open outward
structure,  variants causing impaired hepcidin binding were
found to be localized within the extracellular gate, while vari-
ants causing impaired ubiquitination were found in the periph-
ery of the molecule, suggesting that these latter variants inter-
fere with appropriate folding after hepcidin binding.8 These
findings provide a molecular basis for the observed cellular dis-
tribution pattern of the type 4B iron overload in patients and
the behavior in functional tests performed for these hepcidin-
resistant gain-of-function variants (Figure 1B). 
The study by Ka et al., published in this issue, provides inter-
esting insights into the pathophysiologic mechanisms involved
in ferroportin disease caused by loss-of-function variants. They
describe 22 patients from six independent families with hyper-
ferritinemia,  a normal TSAT and the heterozygous presence of
the Arg178Gln variant. The serum hepcidin levels determined
in two patients were above the reference range. The hepatic
iron content, estimated by MRI methodology in three of the
patients, was mildly elevated and a liver biopsy, performed in
one patient, revealed predominant iron deposition in Kupffer
cells. Although Arg178Gln displayed a reduced export of 55Fe
out of transfected HEK293T cells, the variant was properly
localized on the cellular membrane with disappearance after
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hepcidin exposure. Based on both the clinical phenotype
and functional tests the variant was assigned as a hepcidin
sensitive loss-of-function variant. In the open outward con-
formation of the 3D structure, using Bdellovibrio bacteriovorus
Bd2019 as the template, the demonstrated non-covalent
interaction between Arg178 and Asp473 (located on the N-
and C-lobe, respectively) was assumed to be involved in the
stabilization of the open outward conformation needed to
preserve iron egress. Indeed, the Asp473Ala ferroportin
variant was also properly expressed on the membrane with
a nearly total loss of iron export capacity. In most loss-of-
function variants the abolished iron transport is attributed
to defective expression of ferroportin on the membrane. Ka
et al., however, provide evidence for interference in the sta-
bilization of the conformation state, i.e., the open outward
state, in the Arg178Gln variant as an alternative mechanism
for diminished iron transport, despite the proper membrane
expression of this variant. Further exploration of the amino-
Figure 1. Model displaying  cellular iron flows  in patients with loss-of-function ferroportin variants as compared to physiological conditions and patients with gain-
of-function ferroportin variants and IRIDA. Ferroportin activity  in the enterocyte, macrophage and hepatocyte in physiological steady state conditions (A), hepcidin-
resistant gain-of-function (GOF) (B), iron refractory iron deficiency anemia (IRIDA) (C), loss-of-function (LOF) with mislocalisation on the membrane (D), membrane
expressed destabilized  and hepcidin sensitive LOF (E), membrane expressed destabilized LOF (F). Physiologically, iron availability for erythropoiesis (in the form of
transferrin bound iron ( ) is systemically regulated by the inhibitory effects of the hepatocyte-derived hormone hepcidin ( ) on the activity of ferroportin  ( ). This
regulatory system contributes to the regulation of  intracellular iron ( )  and ferritin bound iron ( ) levels, serum iron ( ) concentration, transferrin saturation (TSAT)
( ) and serum ferritin ( ) concentration. In hepcidin-resistant GOF, there is an increased non-impressionable iron export out of macrophages with continuous ente-
rocyte iron transport with iron deposition in  hepatocytes. In IRIDA, ferroportin action is inhibited by (for body iron status) inappropriately elevated hepcidin leading
to decreased enterocyte iron resorption and diminished ferric-transferrin availability for the erythroblast with the sequestering of some iron, derived from ery-
throphagocytosis, within the macrophage. In patients with LOF variants there is decreased iron transport out of the macrophage leading to  iron sequestration in
these cells, but the mechanism of the apparently relatively increased enterocyte iron export with subsequent body iron overload is not yet fully elucidated. Clinically
observed changes in serum iron, and ferritin concentration and TSAT in the various conditions are depicted by the size of the rectangles in the lower right-hand side
of the panels. DMT: divalent metal transporter; tfr: transferrin receptor-1; fe: iron. Transferrin ( ).
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acid interaction network in various ferroportin conforma-
tion states may reveal additional sites essential for stabiliza-
tion and provide molecular explanation for defective iron
egress in variants without defective membrane expression,
such as Arg88Gly, Leu129Pro, Ile152Phe and Asn174Ile.9-11
Notwithstanding the importance of this finding, it does
not clarify the iron overload observed in these patients.
Moreover, as reported by Ka and colleagues, it is notable
that the patients with a loss-of-function variant ferroportin,
that completely disappears from the cellular membrane
after exposure to hepcidin, have no anemia and intensive
phlebotomy regimens were reported to be well tolerated. In
patients with defective iron export transport due to a loss-
of-function variant, either due to mislocalization or improp-
er folding, one might expect diminished enterocyte iron
absorption leading to a phenotype similar to that described
for iron-refractory iron deficiency (IRIDA). In IRIDA, muta-
tions in the TMPRSS6 gene result in inappropriately elevat-
ed serum hepcidin levels with diminished ferroportin activ-
ity and a variable degree of iron deficiency anemia, unre-
sponsive to oral iron treatment, and intra-enterocyte iron
retention in experimental animals (Figure 1C).12,13
Experimental animals with diminished ferroportin activity
due to monoallelic wild-type ferroportin expression also
display iron deficiency anemia.2 This is in contrast to the
situation in patients with diminished ferroportin activity
due to loss-of-function ferroportin variants which is char-
acterized by iron overload, normal circulating hemoglobin
concentrations and absence of intra-enterocyte iron (evalu-
ated in a limited number of patients) (Figure 1D,E).14 It
appears that in the enterocyte diminished ferroportin activ-
ity due to decreased activity of wild-type ferroportin has a
different effect on iron export capacity than decreased fer-
roportin activity caused by a loss-of-function variant. In
addition, the impact of loss-of-function variants on iron
export capacity may be different between macrophages
and enterocytes,  and the results of the functional studies in
HEK293T cells are more predictive for macrophage iron
handling. It has been suggested that in patients with loss-
of-function variants the remaining monoallelic expressed
wild-type ferroportin protein would be sufficient to pre-
serve iron export in cells with low iron turnover, such as
enterocytes, but insufficient to maintain iron export capac-
ity in cells with high iron turnover, such as macrophages,
with subsequent intracellular iron retention in these cells.5
However, this theory may not provide a full explanation
for the state of iron overload in these patients. While the
activity of ferroportin in both enterocytes and
macrophages in the systemic regulation of iron homeosta-
sis is mediated by hepcidin, there is a considerable amount
of experimental data indicating that the regulation of ferro-
portin expression and activity differ between enterocytes
and macrophages. These data include differences in intra-
cellular regulatory mechanisms that fine-tune ferroportin
membrane expression as well as differences in ferroportin
activity upon various systemic stimuli.15-20 The study by Ka
et al. contributes to our understanding of the pathogenic
mechanisms involved in decreased ferroportin activity by
loss-of-function variants. Studies focused on the conse-
quences of these variants on enterocyte iron handling are
warranted to further comprehend the pathophysiology of
this intriguing iron overload disorder.
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